Search
marstacimab (Hympavzi)
Indications:
- prevention of bleeding in patients with hemophilia A & hemophilia B without inhibitors [1] (FDA-approved Oct 2024)
Dosage:
- loading doses 300 mg SQ, then 150 mg SQ weekly
Mechanism of action:
- marstacimab targets the tissue factor pathway inhibitor
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
hematologic agent
References
- Melville NA
Hemophilia: Marstacimab Sustains Long-Term Bleeding Decrease.
Medscape. June 28, 2024
https://www.medscape.com/s/viewarticle/hemophilia-marstacimab-sustains-long-term-bleeding-decrease-2024a1000c2a
- FDA News Release. Oct 11, 2024
FDA Approves New Treatment for Hemophilia A or B
Product is First Non-Factor and Once-Weekly Treatment for Hemophilia B.
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hemophilia-or-b